Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17620862 | 0.83 | HCAR2 (0.35) | ALDH1A1HPGDRAB9A | |
| SCHEMBL17621032 | 0.76 | GAA (0.43) | GAAIRAK4KDM4EALDH1A1POLB | |
| SCHEMBL17620690 | 0.74 | GAA (0.42) | GAAIRAK4KDM4EALDH1A1POLB | |
| SCHEMBL17620687 | 0.74 | GAA (0.42) | GAAIRAK4KDM4EALDH1A1POLB | |
| SCHEMBL17620685 | 0.74 | GAA (0.42) | GAAIRAK4KDM4EALDH1A1POLB | |
| SCHEMBL17620688 | 0.74 | ALDH1A1 (0.42) | GAAIRAK4KDM4EALDH1A1POLB | |
| SCHEMBL17621022 | 0.74 | GAA (0.42) | GAAIRAK4KDM4EALDH1A1POLB | |
| SCHEMBL20518805 | 0.74 | GAA (0.42) | GAAIRAK4KDM4EALDH1A1POLB | |
| SCHEMBL17620703 | 0.73 | GAA (0.41) | GAAIRAK4KDM4EALDH1A1POLB | |
| SCHEMBL2928930 | 0.72 | KDM4E (0.50) | GAAIRAK4KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385069-B2 | Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2019-08-20 | — | — | US | disclosed |
| WO-2016042172-A1 | IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385069-B2 | Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors | S100B, S100P, S100A4 | GAA 3238/4885IRAK4 170/4885KDM4E 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.